Cardeas Pharma specializes in early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.


Cardeas Pharma announces that FDA Grants QIDP Designation and Fast Track Review for the Company’s Antibiotic Combination Product

Company Initiates Phase 2 Study
Seattle, January 8, 2014 Cardeas Pharma Corporation, a biopharmaceutical company focused on the development of innovative therapies for the treatment of multi-drug resistant (MDR) bacterial infections, announced today that the U.S. Food and Drug Administration (FDA) has designated their investigational antibiotic combination product, Amikacin…

Read More